Biosimilar therapy for breast cancer, zoledronic acid for bone metastases, the future of Obamacare under Donald Trump, and more

Published: Jan. 3, 2017, 4 p.m.

Editors\u2019 Summary by Phil B. Fontanarosa, MD, MBA, Executive Editor of JAMA, the Journal of the American Medical Association, for the January 3, 2017 issue